

## Virtual Workshop

# Real world application of AQbD and analytical procedure life cycle management

**DAY 1 - SEP. 30, 2021**  
8<sup>am</sup> – 1<sup>pm</sup> EDT (1 – 6<sup>pm</sup> BST)

**DAY 2 - OCT. 1, 2021**  
8<sup>am</sup> – 12<sup>pm</sup> EDT (1 – 5<sup>pm</sup> BST)



## Event Agenda

Draft as of September 7

### DAY 1: Thursday, September 30, 2021

TIME (EDT/BST)	PRESENTATION
<b>SESSION: Day 1 opening statements</b> Moderators: James Pound & Horacio Pappa	
<b>8:00 – 8:10 AM EDT</b> (1:00 – 1:10 PM BST)	<b>Welcome</b> James Pound, <i>Acting Deputy Director Inspection, Enforcement and Standards Secretary and Scientific Director, MHRA</i> Horacio Pappa, Ph.D., <i>Director, General Chapters, USP</i>
<b>SESSION: Introduction and history of AQbD</b> Moderator: Phil Borman	
<b>8:10 – 8:30 AM EDT</b> (1:10 – 1:30 PM BST)	<b>Introduction and history of AQbD</b> Phil Borman, D.Sc., <i>Senior Fellow and Director of Product Quality, GSK</i>
<b>SESSION: Industry experts share their experiences of adopting the Analytical Target Profile</b> Moderator: Horacio Pappa	
<b>8:30 – 8:50 AM EDT</b> (1:30 – 1:50 PM BST)	<b>Making the most out of the ATP*</b> Peter Hamilton, Ph.D., <i>Analytical Project Expert, Astra Zeneca</i>
<b>8:50 – 9:10 AM EDT</b> (1:50 – 2:10 PM BST)	<b>Using the ATP to drive performance-based changes for analytical procedures</b> Jörg Hoffmann, Ph.D., <i>Director, Reg.CMC Marketed, Merck Healthcare KGaA</i>
<b>9:10 – 9:40 AM EDT</b> (2:10 – 2:40 PM BST)	<b>Panel Discussion / Q&amp;A</b>
<b>9:40 – 9:50 AM EDT</b> (2:40 – 2:50 PM BST)	<b>Break</b>
<b>SESSION: Case studies discussing the adoption of Quality Risk Management Principles in analytical laboratories</b> Moderator: Stephen Maddocks	
<b>9:50 – 10:10 AM EDT</b> (2:50 – 3:10 PM BST)	<b>British Pharmacopoeia Laboratories, how are QRM concepts built into our processes?</b> Stephen Young, <i>Head of Analytical Science, MHRA</i>
<b>10:10 – 10:30 AM EDT</b> (3:10 – 3:30 PM BST)	<b>Quality Risk Management for Analytical procedures</b> Amanda Guiraldelli, Ph.D., <i>Scientific Affairs Manager, USP</i>
<b>10:30 – 11:00 AM EDT</b> (3:30 – 4:00 PM BST)	<b>Panel Discussion / Q&amp;A</b>
<b>11:00 – 11:10 AM EDT</b> (4:00 – 4:10 PM BST)	<b>Break</b>
<b>SESSION: The important role of experimental design in analytical development</b> Moderator: Amir Malek	

<b>11:10 – 11:30 AM EDT</b> (4:10 – 4:30 PM BST)	<b>Application of DOE in Biotherapeutics</b> Joe Callahan, Ph.D., <i>Technical Development Scientist, Genentech</i> Toby Reichenberg, <i>QC/Research Associate, Genentech</i>
<b>11:30 – 11:50 AM EDT</b> (4:30 – 4:50 PM BST)	<b>DOE Lessons learned and best practices</b> Rosario LoBrutto, Ph.D., <i>Executive Director, Head of Scientific Affairs, Sandoz</i>
<b>11:50 AM – 12:10 PM EDT</b> (4:50 – 5:10 PM BST)	<b>Industry experience of DoE</b> Kimber Barnett, Ph.D., <i>Associate Research Fellow, Pfizer</i>
<b>12:10 – 12:50 PM EDT</b> (5:10 – 5:50 PM BST)	<b>Panel Discussion / Q&amp;A</b>
<b>12:50 – 1:00 PM EDT</b> (5:50 – 6:00 PM BST)	<b>Day 1 Closing Remarks</b>

## DAY 2: Friday, October 1, 2021

TIME (EDT/BST)	PRESENTATION
<b>SESSION: Day 2 opening statements</b> Moderator: James Pound & Horacio Pappa	
<b>8:00 – 8:10 AM EDT</b> (1:00 – 1:10 PM BST)	<b>Welcome, Day 1 Recap</b> James Pound, <i>Acting Deputy Director Inspection, Enforcement and Standards Secretary and Scientific Director, MHRA</i> Horacio Pappa, Ph.D., <i>Director, General Chapters, USP</i>
<b>SESSION: AqBd and the Analytical Procedure Lifecycle: replication strategies, control strategies and ongoing verification</b> Moderator: James Pound	
<b>8:10 – 8:30 AM EDT</b> (1:10 – 1:30 PM BST)	<b>Risk assessment techniques in Analytical Control Strategy</b> Phil Nethercote, Ph.D., <i>Independent Consultant</i>
<b>8:30 – 8:50 AM EDT</b> (1:30 – 1:50 PM BST)	<b>Analytical Control Strategy</b> Tim Schofield, M.A., <i>Owner &amp; Consultant, CMC Science, LLC</i>
<b>8:50 – 9:10 AM EDT</b> (1:50 – 2:10 PM BST)	<b>Ongoing performance verification</b> Joachim Ermer, Ph.D., <i>Owner, Ermer Quality Consulting</i>
<b>9:10 – 9:40 AM EDT</b> (2:10 – 2:40 PM BST)	<b>Panel Discussion / Q&amp;A</b>
<b>9:40 – 10:00 AM EDT</b> (2:40 – 3:00 PM BST)	<b>Break</b>
<b>SESSION: BP &amp; USP discuss guidance on AqBd and the Analytical Procedure Lifecycle</b> Moderator: Graham Cook	
<b>10:00 – 10:20 AM EDT</b> (3:00 – 3:20 PM BST)	<b>British Pharmacopoeia AqBd Supplementary chapter and ongoing projects.</b> Laxsaan Elanganathan, MSc., <i>Senior Pharmacopoeial Scientist, MHRA</i>
<b>10:20 – 10:40 AM EDT</b> (3:20 – 3:40 PM BST)	<b>USP chapter &lt;1220&gt;</b> Jane Weitzel, <i>USP Expert Volunteer (Chair of General Chapters, Measurement &amp; Data Quality Expert Committee)</i>
<b>SESSION: Regulatory stories and experiences</b> Moderator: Elena Razzano	
<b>10:40 – 11:00 AM EDT</b> (3:40 – 4:00 PM BST)	<b>MHRA perspective</b> Chris Gray, <i>GMDP inspector/Operations Manager, MHRA</i>

<b>11:00 – 11:20 AM EDT</b> <i>(4:00 – 4:20 PM BST)</i>	<b>U.S. FDA perspective</b> Jinhui Zhang, Ph.D., <i>Chemist, U.S. Food &amp; Drug Administration</i>
<b>11:20 – 11:50 AM EDT</b> <i>(4:20 – 4:50 PM BST)</i>	<b>Panel Discussion / Q&amp;A</b>
<b>11:50 – 12:00 PM EDT</b> <i>(4:50 – 5:00 PM BST)</i>	<b>Workshop Conclusion</b> James Pound, <i>Acting Deputy Director Inspection, Enforcement and Standards Secretary and Scientific Director, MHRA</i> Horacio Pappa, Ph.D., <i>Director, General Chapters, USP</i>